Def Leppard Guitarist Reveals New Short Hair Look at Hellfest
Def Leppard guitarist Vivian Campbell, who recently announced his diagnosis with Hodgkin's lymphoma, unveiled his new, post-chemotherapy look at the music festival Hellfest, which takes place in Clisson, France.
The band is one of the show's headliners, and metal website Blabbermouth posted some fan-recorded video.
Vivian Campbell is on the left and enters around the :15 mark.
Campbell told Blabbermouth:
Obviously, there's a lot of side effects from doing chemo, as I'm sure a lot of your listeners know. Which is one thing that's actually really resonated with me as a result of going public with this is how many other people suffer from cancer of different shapes and forms, you know. It's, unfortunately, a very prevalent disease.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
